950
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Spatial transcriptomic analysis reveals local effects of intratumoral fusobacterial infection on DNA damage and immune signaling in rectal cancer

, , , , , , , , , , , , & ORCID Icon show all
Article: 2350149 | Received 04 Nov 2023, Accepted 26 Apr 2024, Published online: 06 May 2024

References

  • Qi Y, Wu HM, Yang Z, Zhou YF, Jin L, Yang MF, Wang F-Y. New insights into the role of oral microbiota dysbiosis in the pathogenesis of inflammatory bowel disease. Dig Dis Sci. 2022;67(1):42–14. doi:10.1007/s10620-021-06837-2.
  • Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J. et al. Genomic analysis identifies association of fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–298. doi:10.1101/gr.126573.111.
  • Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T. et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443–1448. doi:10.1126/science.aal5240.
  • Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381–1390. doi:10.1007/s10096-014-2081-3.
  • Brennan CA, Garrett WS. Fusobacterium nucleatum — symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17(3):156–166. doi:10.1038/s41579-018-0129-6.
  • Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, Chen Z, Wang L, Long Y, Hou T. et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. doi:10.1080/19490976.2021.1980347.
  • Borowsky J, Haruki K, Lau MC, Dias Costa A, Väyrynen JP, Ugai T, Arima K, da Silva A, Felt KD, Zhao M. et al. Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment. Clin Cancer Res. 2021;27(10):2816–2826. doi:10.1158/1078-0432.CCR-20-4009.
  • Gethings-Behncke C, Coleman HG, Jordao HWT, Longley DB, Crawford N, Murray LJ, Kunzmann AT. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(3):539–548. doi:10.1158/1055-9965.EPI-18-1295.
  • Oh HJ, Kim JH, Bae JM, Kim HJ, Cho N-Y, Kang GH. Prognostic impact of fusobacterium nucleatum depends on combined tumor location and microsatellite instability status in stage II/III colorectal cancers treated with adjuvant chemotherapy. J Pathol Transl Med. 2019;53(1):40–49. doi:10.4132/jptm.2018.11.29.
  • Yamaoka Y, Suehiro Y, Hashimoto S, Hoshida T, Fujimoto M, Watanabe M, Imanaga D, Sakai K, Matsumoto T, Nishioka M. et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53(4):517–524. doi:10.1007/s00535-017-1382-6.
  • Salvucci M, Crawford N, Stott K, Bullman S, Longley DB, Prehn JHM. Patients with mesenchymal tumours and high fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC). Gut. 2021;gutjnl-2021–325193. doi:10.1136/gutjnl-2021-325193.
  • Wang Y, Wen Y, Wang J, Lai X, Xu Y, Zhang X, Zhu X, Ruan C, Huang Y. Clinicopathological differences of high fusobacterium nucleatum levels in colorectal cancer: a review and meta-analysis. Front Microbiol. 2022;13:945463. doi:10.3389/fmicb.2022.945463.
  • Lee DW, Han SW, Kang JK, Bae JM, Kim HP, Won JK, Jeong S-Y, Park KJ, Kang GH, Kim T-Y. et al. Association between fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–3395. doi:10.1245/s10434-018-6681-5.
  • McCawley N, Clancy C, O’Neill BD, Deasy J, McNamara DA, Burke JP. Mucinous rectal adenocarcinoma is associated with a poor response to Neoadjuvant Chemoradiotherapy: a systematic review and meta-analysis. Diseases Of The Colon & Rectum. 2016;59(12):1200–1208. doi:10.1097/DCR.0000000000000635.
  • Bong JW, Gim JA, Ju Y, Cheong C, Lee SI, Oh SC, Min B-W, Kang S. Prognosis and sensitivity of adjuvant chemotherapy in mucinous colorectal adenocarcinoma without distant metastasis. Cancers. 2022;14(5):1297. doi:10.3390/cancers14051297.
  • Reynolds IS, Thomas V, O’Connell E, Fichtner M, McNamara DA, Kay EW, Prehn JHM, Burke JP, Furney SJ. Mucinous adenocarcinoma of the rectum: a whole genome sequencing study. Front Oncol. 2020;10:1682. doi:10.3389/fonc.2020.01682.
  • Duggan WP, Salvucci M, Kisakol B, Lindner AU, Reynolds IS, Dussmann H, Fay J, O’Grady T, Longley DB, Ginty F. et al. Increased fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcome. J Mol Med. 2023;101(7):829–841. doi:10.1007/s00109-023-02324-5.
  • Zhao Y, Ge X, Xu X, Yu S, Wang J, Sun L. Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer. J Cancer Res Clin Oncol. 2019;145(12):3005–3019. doi:10.1007/s00432-019-03041-8.
  • de Vries, NL, Mahfouz A, Koning F, de Miranda N, de Vries NL. Unraveling the complexity of the cancer microenvironment with multidimensional genomic and cytometric technologies. Front Oncol. 2020;10:1254. doi:10.3389/fonc.2020.01254.
  • Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, Hoang M, Jung J, Liang Y, McKay-Fleisch J. et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586–599. doi:10.1038/s41587-020-0472-9.
  • Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975.
  • Mancini R, Pattaro G, Diodoro MG, Sperduti I, Garufi C, Stigliano V, Perri P, Grazi GL, Cosimelli M. Tumor regression grade after neoadjuvant chemoradiation and surgery for low rectal cancer evaluated by multiple correspondence analysis: Ten years as minimum follow-up. Clin Colorectal Cancer. 2018;17(1):e13–e9. doi:10.1016/j.clcc.2017.06.004.
  • Casasanta MA, Yoo CC, Udayasuryan B, Sanders BE, Umaña A, Zhang Y, Peng H, Duncan AJ, Wang Y, Li L. et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020;13(641). doi:10.1126/scisignal.aba9157.
  • Ortogero NY, Vitancol R, Griswold M, Henderson D. GeomxTools: NanoString GeoMx Tools. R package version 3.4.0. 2023.
  • Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M. et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573–87.e29. doi:10.1016/j.cell.2021.04.048.
  • Cheng H, Zhang N, Pati D. Cohesin subunit RAD21: from biology to disease. Gene. 2020;758:144966. doi:10.1016/j.gene.2020.144966.
  • Gennady K, Vladimir S, Nikolay B, Boris S, Maxim NA, Alexey S. Fast gene set enrichment analysis. bioRxiv. 2021;060012.
  • Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5.
  • Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
  • Danaher P, Kim Y, Nelson B, Griswold M, Yang Z, Piazza E, Beechem JM. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. Nat Commun. 2022;13(1):385. doi:10.1038/s41467-022-28020-5.
  • Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–16.e11. doi:10.1016/j.cell.2018.02.052.
  • Vandooren J, Itoh Y. Alpha-2-macroglobulin in inflammation, immunity and infections. Front Immunol. 2021;12:12. doi:10.3389/fimmu.2021.803244.
  • Zhang Y, Chen Y, Huang J, Wu X, Tang R, Huang Q, Xu Y, Peng X, Fu K, Xiao S. et al. Mucinous histology is associated with poor prognosis in locally advanced colorectal adenocarcinoma treated with postoperative first-line adjuvant chemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(10):2075–2081. doi:10.1016/j.ejso.2022.06.024.
  • Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–63.e16. doi:10.1016/j.cell.2017.07.008.
  • Zaborowski AM, Winter DC, Lynch L. The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. Br J Cancer. 2021;125(10):1341–1349. doi:10.1038/s41416-021-01475-x.
  • Ma R, Yuan D, Guo Y, Yan R, Li K. Immune effects of γδ T cells in colorectal cancer: a review. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.01600.
  • Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, Hartman J, Religa P, Morikawa H, Ishii Y. et al. Pericyte–fibroblast transition promotes tumor growth and metastasis. Proc Natl Acad Sci. 2016;113(38):E5618–E27. doi:10.1073/pnas.1608384113.
  • Hsueh C-Y, Lau H-C, Huang Q, Gong H, Sun J, Cao P, Hu C, Zhang M, Tao L, Zhou L. et al. Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck. Cancer. 2022;128(17):3170–3184. doi:10.1002/cncr.34338.
  • Guo P, Tian Z, Kong X, Yang L, Shan X, Dong B, Ding X, Jing X, Jiang C, Jiang N. et al. FadA promotes DNA damage and progression of fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J Exp Clin Cancer Res. 2020;39(1):202. doi:10.1186/s13046-020-01677-w.
  • Okita Y, Koi M, Takeda K, Ross R, Mukherjee B, Koeppe E, Stoffel EM, Galanko JA, McCoy AN, Keku TO. et al. Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. Gut Pathog. 2020;12(1):46. doi:10.1186/s13099-020-00384-3.
  • Nakad R, Schumacher B. DNA damage response and immune defense: links and mechanisms. Front Genet. 2016;7. doi:10.3389/fgene.2016.00147.
  • Cores Ziskoven P, Nogueira AVB, Gutierrez LS, Weusmann J, Eick S, Buduneli N, Deschner J. Apelin enhances the effects of fusobacterium nucleatum on periodontal ligament cells in vitro. Int J Mol Sci. 2023;24(5):4733. doi:10.3390/ijms24054733.
  • Despins CA, Brown SD, Robinson AV, Mungall AJ, Allen-Vercoe E, Holt RA, Pujol N. Modulation of the Host cell transcriptome and epigenome by fusobacterium nucleatum. mBio. 2021;12(5):e0206221. doi:10.1128/mBio.02062-21.
  • Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy. Antioxidants. 2021;10(2):174. doi:10.3390/antiox10020174.
  • Cao P, Chen Q, Shi C, Wang L, Gong Z. Fusobacterium nucleatum promotes the development of acute liver failure by inhibiting the NAD+ salvage metabolic pathway. Gut Pathog. 2022;14(1):29. doi:10.1186/s13099-022-00503-2.
  • Zhou J, Liu L, Wu P, Zhao L, Wu Y. Fusobacterium nucleatum accelerates atherosclerosis via macrophage-driven aberrant proinflammatory response and lipid metabolism. Front Microbiol. 2022;13. doi:10.3389/fmicb.2022.798685.
  • Chang NC. Autophagy and stem cells: self-eating for self-renewal. Front Cell Dev Biol. 2020;8. doi:10.3389/fcell.2020.00138.
  • Mahgoub E, Taneera J, Sulaiman N, Saber-Ayad M. The role of autophagy in colorectal cancer: impact on pathogenesis and implications in therapy. Front Med. 2022;9. doi:10.3389/fmed.2022.959348.
  • Zhou Z, Chen J, Yao H, Hu H. Fusobacterium and colorectal cancer. Front Oncol. 2018;8. doi:10.3389/fonc.2018.00371.
  • Galeano Niño JL, Wu H, LaCourse KD, Kempchinsky AG, Baryiames A, Barber B, Futran N, Houlton J, Sather C, Sicinska E. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022;611(7937):810–817. doi:10.1038/s41586-022-05435-0.